Welcome to our dedicated page for Phibro Animal news (Ticker: PAHC), a resource for investors and traders seeking the latest updates and insights on Phibro Animal stock.
Phibro Animal Health Corporation (Nasdaq: PAHC) is a diversified global animal health and nutrition company with operations across Animal Health, Mineral Nutrition, and Performance Products. This news page aggregates company-issued updates and other coverage related to PAHC stock, helping readers follow developments that Phibro discloses through press releases and regulatory communications.
Phibro’s news flow frequently includes financial results and guidance, such as quarterly and full-year earnings releases and updates to financial outlook for future fiscal years. These announcements often detail net sales by segment, trends in medicated feed additives (MFAs), nutritional specialty products, vaccines, mineral nutrition products, and performance products, as well as commentary on factors like product demand, foreign currency impacts, and operating expenses.
Investors can also expect corporate and strategic announcements, including information about acquisitions or portfolio additions, such as the referenced MFA portfolio acquired from Zoetis, Inc., and enterprise programs like Phibro Forward, which the company describes as focused on efficiency, growth, and cultural engagement. Leadership and governance updates, including planned executive transitions and matters presented at the annual meeting of stockholders, are typically communicated through press releases and accompanying SEC filings.
Product and pipeline-related news is another key category. Phibro has highlighted developments in companion animal oral health, including the licensing agreement with Lighthouse Pharmaceuticals, Inc. for a proprietary compound for canine periodontal care and the national launch of Restoris piezoelectric dental gel for dogs with periodontal disease. Such releases describe product mechanisms, study results, and distribution plans.
In addition, Phibro issues dividend declarations, notices of participation in investor conferences, and details on upcoming webcasts and conference calls to discuss results. Readers interested in PAHC can use this page to monitor these recurring updates and review the company’s own descriptions of its performance, strategy, and product initiatives.
The Board of Directors of Phibro Animal Health Corporation (Nasdaq:PAHC) announced a quarterly cash dividend of $0.12 per share on its Class A and Class B common stock. This dividend will be payable on September 22, 2021, to stockholders recorded on September 1, 2021. Phibro is a global developer, manufacturer, and supplier of animal health and mineral nutrition products aimed at enhancing food production efficiency while reducing resource use.
Phibro Animal Health Corporation (NASDAQ:PAHC) reported Q3 FY2021 net sales of $212 million, a marginal increase of less than 1% year-over-year. Net income fell to $12 million, a decrease of 10%, with diluted EPS at $0.30, down by 9%. For the nine-month period, net sales reached $613 million, up slightly, while net income surged by 34% to $37 million. Adjusted EBITDA for Q3 declined by 7% to $28 million. The company received EU GMP approval for a new vaccine facility in Ireland and sees potential for a strong Q4. Financial guidance suggests Q4 net sales between $213-217 million.
The Board of Directors of Phibro Animal Health Corporation (Nasdaq:PAHC) has declared a quarterly cash dividend of $0.12 per share on its Class A and Class B common stock. This dividend is payable on June 23, 2021, to shareholders on record as of June 2, 2021. Phibro Animal Health is a global developer and manufacturer of animal health and nutrition products aimed at promoting sustainable livestock production.
Phibro Animal Health Corporation (NASDAQ:PAHC) will announce its third quarter financial results on May 6, 2021, after market close. A conference call and webcast will follow on May 7, 2021, at 9:00 AM Eastern Time. Interested parties can access the call via phone or online, with a replay available two hours post-event. Phibro specializes in developing and supplying a range of animal health and mineral nutrition products aimed at supporting livestock health and sustainability. For details, visit investors.pahc.com.
Phibro Animal Health Corporation (NASDAQ:PAHC) will participate in the Bank of America Securities 2021 Virtual Healthcare Conference. The event is scheduled for Tuesday, May 11, 2021, at 4:15 PM ET. Key executives including Chairman and CEO Jack Bendheim, CFO Damian Finio, and Executive VP Daniel Bendheim will address analysts and investors. The live audio presentation will be accessible on the Phibro Investor Relations Website, with a replay available post-event.
Phibro Animal Health Corporation (NASDAQ:PAHC) will participate in the Barclays Virtual Global Healthcare Conference on March 10, 2021, at 3:35 PM Eastern Time. The company's Chairman and CEO, Jack Bendheim, along with CFO Damian Finio, will address financial analysts and investors during the session. Interested parties can access the live audio presentation on the Phibro Investor Relations Website, with a replay available afterward. Phibro focuses on animal health and mineral nutrition products to support sustainable livestock practices.
Phibro Animal Health Corporation (NASDAQ:PAHC) will participate in the Bank of America Merrill Lynch 2021 Virtual Animal Health Summit on February 25, 2021. During the event, Chairman Jack Bendheim and CFO Damian Finio will address financial analysts and investors at 12:40 PM Eastern Time. The live audio presentation can be accessed on the company's Investor Relations website, with an archived replay available afterward. Phibro focuses on animal health and nutrition products, aimed at supporting sustainable livestock production.
Phibro Animal Health Corporation (NASDAQ:PAHC) reported its second-quarter financial results for the period ending December 31, 2020. Net sales reached $206 million, down 4% from the previous year, while net income improved to $13 million, an 8% increase. Diluted EPS increased by 10% to $0.32. The company noted challenges in international demand, particularly in China and Latin America. Despite sales declines, gross profit slightly improved. For Q3 2021, Phibro projects net sales between $205-208 million and net income of $11-12 million.
The Board of Directors of Phibro Animal Health Corporation (Nasdaq: PAHC) declared a quarterly cash dividend of $0.12 per share on its Class A and Class B common stock. This dividend will be payable on March 24, 2021, to stockholders of record as of the close of business on March 3, 2021. The company focuses on developing and supplying animal health and nutrition products, assisting veterinarians and farmers in producing healthy food sustainably.
Phibro Animal Health Corporation (NASDAQ: PAHC) is set to release its second-quarter financial results on February 3, 2021, post-market close. A conference call and webcast will follow on February 4, 2021, at 9:00 AM ET, allowing stakeholders to engage with management. Interested parties can access the presentation via their investor relations website. Phibro focuses on providing a diverse range of animal health and mineral nutrition products, supporting sustainable food production with fewer natural resources.